Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL
Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.
Trouble With the Curve: Beyond the Basics With Kaplan-Meier
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier curves.
Dr. Banerjee on the Rationale to Create a Supportive Mobile Health App for CAR T-Cell Therapy
Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers to use throughout the therapeutic process.
Prepping for Your Invited Oral Presentation
Breaking down your oral presentation into specific content-related and
delivery-related domains can help you remember what
to rehearse and what to include.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512